Evaluating a new injection for estrogen-free female contraception
CCTN-PHARMACOKINETIC / PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION - OREGON
This study is testing a new long-lasting birth control shot called levonorgestrel butanoate, which is made especially for women, especially those who are overweight and at risk for blood clots, to see if it works well and is safe as an alternative to regular birth control pills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11042052 on NIH RePORTER |
What this research studies
This research investigates a new long-acting injectable contraceptive called levonorgestrel butanoate (LB), designed specifically for women, particularly those who are obese and at risk for venous thromboembolism (VTE). The study aims to assess the pharmacokinetics and pharmacodynamics of LB to determine its effectiveness and safety as an alternative to traditional estrogen-containing contraceptives. By focusing on an estrogen-free option, the research seeks to provide a more accessible and safer contraceptive method for women who may struggle with adherence to daily pills. Participants will be involved in a clinical trial that evaluates how well this new formulation works in preventing pregnancy.
Who could benefit from this research
Good fit: Ideal candidates for this research are women, especially those who are obese and seeking effective contraception without the risks associated with estrogen.
Not a fit: Patients who are not seeking contraception or those who do not have concerns related to estrogen use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more convenient contraceptive option for women, particularly those at higher risk for VTE.
How similar studies have performed: Previous research has shown success with other long-acting contraceptive methods, indicating potential for this novel approach.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Jensen, Jeffrey — Oregon Health & Science University
- Study coordinator: Jensen, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.